Abstract:BACKGROUND:Primary adenocarcinoma of the urinary bladder is rare. The molecular and cellular events leading to its pathogenesis are not well delineated. The goal of this study was to investigate p53 and p16 expression, as well as HPV status, in a relatively large series of primary bladder adenocarcinomas.MATERIALS AND METHODS:Thirty six cases of urinary bladder adenocarcinoma were chosen from participating institutions. The diagnosis and available clinical history were reviewed in each case. Immunostains for p53, p16 and HPV and high-risk and low-risk HPV-ISH were performed on all tumors.RESULTS:Patients had an average age of 61 years with a male predominance (1.5 ∶ 1 male ∶ female ratio). The average tumor size in cystectomy specimens was 4.3 cm. Of the cases managed by transurethral resection, 40% were pT2 at the time of diagnosis. In cystectomy specimens, 77% were either pT3 or pT4. Strong nuclear p16 expression was seen in 67% of all cases and p53 expression was present in 58% of the cases. Expression of both markers was seen in 33% of cases. Expression of p16 or p53 alone was present in 12 (33%) and 9 (25%) cases, respectively. Neither marker was expressed in only 3 (8%) of the tumors. No significant correlation between clinical variables and any of the markers we studied was identified. No HPV infection was detected in any case.CONCLUSIONS:Expression of p53 and/or p16 is very common in urinary bladder adenocarcinoma. These findings implicate a high likelihood that alterations in these cell cycle proteins contribute to the pathogenesis of these tumors. Despite frequent immunohistochemical labeling for p16, no evidence of HPV infection was found.

Significance of Study on P16 Gene Loss in Primary Transitional Cell Carcinomas of Urinary Bladder

Study of p16 gene loss and mutation in primary transitional cell carcinomas of urinary bladder

MTS1 Product P16 Expression in Bladder Transitional Cell Carcinoma

The Expression of p16 and p53 Tumor Suppressor Gene in Bladder Carcinoma

The Role of MTS1 Gene Mutation in Primary Transitional Cell Carcinomas of Urinary Bladder

Expressions of P16 Protein and PCNA in Transitional Cell Carcinoma of the Urinary Bladder and Their Implications

Effects of P16 Gene Aberration on the Proliferative Activity of Bladder Transitional Cell Cancer

An Analysis of the Relationship between 5'CpG Island Methylation of P16 Gene and Tumor Aggressive Behavior in Transitional Cell Carcinomas of Uronary Bladded

Expression of Bmi-1 and p16 gene in transitional cell carcinoma of bladder

Expression of P16 Protein and Cyclind1 Protein in Transitional Cell Carcinoma(tcc) of Urinary Bladder and Their Implications

Companied P16 genetic and protein status together providing useful information on the clinical outcome of urinary bladder cancer

Effects of Transfer of P16 Gene on the Proliferation and Apoptosis of Human Bladder Cancer Cell

Relationship between the expression of mutant P53 and PCNA and their clinical significances in transitional cell carcinoma of the bladder

Experimental Study on Biological Specificity of P16 Gene Transferring into Bladder Cancer Cell Line

The Relationship Between the Expression of Mutant p53 and VEGF and the Clinical Significances in Transitional Cell Carcinoma of the Bladder

Expression of PCNA in Human Bladder Transitional Cell Carcinoma and Its Clinical Significance

The Abnormality of P16 Gene and the Expression of P16 Protein in Primary Renal Cell Carcinoma

Expression of PTEN in human transitional cell carcinoma of bladder and its clinical significance

Study of Telomerase Activity in Transitional Cell Carcinoma of the Bladder

Research on the relationship between telomerase activity and the clinically pathological characteristic in bladder cancer

The Expression Patterns of P53 and P16 and an Analysis of a Possible Role of HPV in Primary Adenocarcinoma of the Urinary Bladder.